Evaluating new treatments for anaplastic thyroid cancer

References

• Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486–497.
   PubMed Web of Science ®Google Scholar
• Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1–122.
   PubMed Web of Science ®Google Scholar
• Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337–386.
   PubMed Web of Science ®Google Scholar
• Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg. 2011;19(2):113–118.
   PubMed Web of Science ®Google Scholar
• Lloyd R, Osamura R, Klöppel G, et al. WHO classification of tumours of endocrine organs. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573–1604.
   PubMed Web of Science ®Google Scholar
• De Leo S, Trevisan M, Fugazzola L. Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 2020;13(1):17.
   PubMed Web of Science ®Google Scholar
• Xu B, Fuchs T, Dogan S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid. 2020;30(10):1505–1517.
   PubMed Web of Science ®Google Scholar
• Janz TA, Neskey DM, Nguyen SA, et al. Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study. World J Otorhinolaryngol - head neck Surg. 2019;5(1):34–40
   PubMedGoogle Scholar
• Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020;6(9):1397–1404.
   PubMed Web of Science ®Google Scholar
• de Ridder M, Nieveen van Dijkum E, Engelsman A, et al. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur J Endocrinol. 2020;183(2):203–209.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350(jan02 1):g7647.
   PubMedGoogle Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103.
   PubMed Web of Science ®Google Scholar
• Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kiyota N, Yamazaki T, et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15(7):717–726.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Brose MS, Sherman EJ, et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021;39(21):2359–2366.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Ito Y, Onoda N, Ito K-I, et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid. 2017;27(9):1142–1148.
   PubMed Web of Science ®Google Scholar
• Sherman EJ, Dunn LA, Ho AL, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017;123(21):4114–4121.
   PubMed Web of Science ®Google Scholar
• Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res. 2003;9(8):2882–2886.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–1945.
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66(11):5549–5554.
   PubMed Web of Science ®Google Scholar
• Malaguarnera R, Chen K-Y, Kim T-Y, et al. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab. 2014;99(10):E1976–87.
   PubMed Web of Science ®Google Scholar
• Guigon CJ, Fozzatti L, Lu C, et al. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis. 2010;31(7):1284–1291.
   PubMed Web of Science ®Google Scholar
• Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009;23(6):377–389.
   PubMed Web of Science ®Google Scholar
• Ravaud A, de la Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 2017;76:110–117.
   PubMed Web of Science ®Google Scholar
• Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066.
   PubMed Web of Science ®Google Scholar
• Deeken-Draisey A, Yang G-Y, Gao J, et al. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. Hum Pathol. 2018;82:140–148.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
   PubMed Web of Science ®Google Scholar
• Kurata K, Onoda N, Noda S, et al. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. Int J Oncol. 2016;49(6):2303–2308.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13.
   PubMed Web of Science ®Google Scholar
• Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid. 2019;29(8):1036–1043.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-Altered thyroid cancers. N Engl J Med. 2020;383(9):825–835.
   PubMed Web of Science ®Google Scholar
• Leroy L, Bonhomme B, Le Moulec S, et al. Remarkable response to ceritinib and brigatinib in an anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma previously treated with crizotinib. Thyroid. 2020;30(2):343–344.
   PubMed Web of Science ®Google Scholar
• Onoda N, Nakamura M, Aomatsu N, et al. Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation. Mol Clin Oncol. 2015;3(3):522–526.
   PubMedGoogle Scholar
• Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a Phase II clinical trial. J Clin Endocrinol Metab. 2017;102(2):698–707.
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Busaidy NL, Chau NG, et al. genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a Phase II study. Clin Cancer Res. 2018;24(7):1546–1553.
   PubMed Web of Science ®Google Scholar
• Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab. 2017;102(6):1943–1950.
   PubMed Web of Science ®Google Scholar
• Ahn S, Kim TH, Kim SW, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24(2):97–106.
   PubMed Web of Science ®Google Scholar
• Cantara S, Bertelli E, Occhini R, et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine. 2019;64(1):122–129.
   PubMed Web of Science ®Google Scholar
• Naing A, Gainor JF, Gelderblom H, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020;8(1):e000530.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620–2627.
   PubMed Web of Science ®Google Scholar
• Iyer PC, Dadu R, Gule-Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68.
   PubMedGoogle Scholar
• ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine; [Cited 2022 Jan 4]. Available from: https://clinicaltrials.gov/.
   Google Scholar
• Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer. 1978;41(6):2267–2275.
   PubMed Web of Science ®Google Scholar
• Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol. 2014;21(5):1665–1670.
   PubMed Web of Science ®Google Scholar
• Van der Laan BFAM, Freeman JL, Tsanq RW, et al. The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocr Pathol. 1993;4(4):215–221.
   PubMed Web of Science ®Google Scholar
• Spires JR, Schwartz MR, Miller RH. Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg. 1988;114(1):40–44.
   PubMedGoogle Scholar
• Jannin A, Escande A, Al Ghuzlan A, et al. Anaplastic thyroid carcinoma: an update. Cancers (Basel). 2022;14(4):1061.
   PubMed Web of Science ®Google Scholar
• Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27(18):2977–2982.
   PubMed Web of Science ®Google Scholar
• Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161–1170.
   PubMed Web of Science ®Google Scholar
• García-Rostán G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199–10207.
   PubMed Web of Science ®Google Scholar
• Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab. 2000;85(1):302–308.
   PubMed Web of Science ®Google Scholar
• Wiseman SM, Masoudi H, Niblock P, et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 2006;191(5):581–587.
   PubMed Web of Science ®Google Scholar
• O’Neill JP, Shaha AR. Anaplastic thyroid cancer. Oral Oncol. 2013;49(7):702–706.
   PubMed Web of Science ®Google Scholar
• Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010;95(1):450–455.
   PubMed Web of Science ®Google Scholar
• Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 2006;12(6):1785–1793.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Dadu R, Iyer P, et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020;30(9):1288–1296.
   PubMed Web of Science ®Google Scholar
• Cabanillas M, Busaidy N, Dadu R, et al. OR27-6 combination vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E mutated anaplastic thyroid cancer (ATC): initial safety and feasibility. J Endocr Soc. 2019;3(Supplement_1):OR27–6.
   Google Scholar
• Hall MN. mTOR-what does it do? Transplant Proc. 2008;40(10 Suppl):S5–8.
   PubMedGoogle Scholar
• Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology. 2008;87(3):168–181.
   PubMed Web of Science ®Google Scholar
• Zhang G-Q, Wei W-J, Song H-J, et al. Programmed cell death-ligand 1 overexpression in thyroid cancer. Endocr Pract. 2019;25(3):279–286.
   PubMed Web of Science ®Google Scholar